

Datasheet for ABIN2192031 anti-PRTN3 antibody (FITC)



Publications



Go to Product page

_						
	1//	Д	rv	16	٦/	٨
U	W	\vdash	ΙV	Ιt	٦,	/V

Quantity:	100 μg
Target:	PRTN3
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This PRTN3 antibody is conjugated to FITC
Application:	Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoassay (IA)
Product Details	
Clone:	WGM2
Clone: Sterility:	WGM2 0.2 µm filtered
Sterility:	
Sterility: Target Details	0.2 μm filtered

Wegener's granulomatosis (WG). ANCA directed against PR3 (PR3-ANCA) can interfere with the binding of PR3 to its physiological inhibitor alpha1-antitrypsin (alpha1-AT) and with the proteolytic activity of PR3. At the site of inflammation PR3 can cleave the complex between these inhibiting ANCA and PR3 itself, leaving active PR3. Autoantibodies to PR3 are potent activators of the 5-lipoxygenase pathway in primed human neutrophils. Extracellular free arachidonic acid, as present at an inflammatory focus, synergizes with such autoantibodies to evoke full-blown lipid mediator generation, granule secretion and respiratory burst. Proteinase 3 (PR3) is a neutral serine proteinase, which is localized in the azurophilic granules of neutrophils and in granules of monocytes and can be detected in the membrane of secretory vesicles. PR3 degrades a number of extracellular matrix proteins such as elastin and inactivates human C1 inhibitor. Membrane-associated PR3 is also able to activate caspase-3 without triggering apoptosis of neutrophils, which is possibly a neutrophil survival mechanism. In addition, PR3 is involved in myeloid differentiation and is, therefore, also called myeloblastin. Monoclonal antibody WGM2 blocks the PR3 activity and partially inhibits the binding of human PR3-ANCA to PR3.

Application Details

Application Notes:	For flow cytometry, Western blotting and immunohistology dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Restrictions:	For Research Use only
Handling	
Buffer:	PBS, containing 1 % bovine serum albumin and 0.02 % sodium azide.
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	4 °C
Storage Comment:	Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Expiry Date:	12 months

Product cited in:

Van Der Geld, Limburg, Kallenberg: "Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies." in: **Clinical and experimental immunology**, Vol. 118, Issue 3, pp. 487-96, (2000) (PubMed).

Grimminger, Hattar, Papavassilis, Temmesfeld, Csernok, Gross, Seeger, Sibelius: "Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation." in: **The Journal of experimental medicine**, Vol. 184, Issue 4, pp. 1567-72, (1996) (PubMed).

Braun, Csernok, Rögener-Schwarz, Ludwig, Müller-Hermelink, Gross, Feller: "Monoclonal antibody WGM1 directed against proteinase 3: an immunohistochemical marker for naphthol ASD chloroacetate." in: **Hematological oncology**, Vol. 14, Issue 2, pp. 83-90, (1996) (PubMed).

Braun, Csernok, Gross, Müller-Hermelink: "Proteinase 3, the target antigen of anticytoplasmic antibodies circulating in Wegener's granulomatosis. Immunolocalization in normal and pathologic tissues." in: **The American journal of pathology**, Vol. 139, Issue 4, pp. 831-8, (1991) (PubMed).

Csernok, Lüdemann, Gross, Bainton: "Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis." in: **The American journal of pathology**, Vol. 137, Issue 5, pp. 1113-20, (1990) (PubMed).